Suspension of trading
Quotes eFFECTOR Therapeutics, Inc. Deutsche Boerse AG
Stocks
LWK1
US28202V1089
Biotechnology & Medical Research
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.075 EUR | +0.47% |
|
-8.12% | -88.97% |
| 24-09-10 | Tyra Biosciences Names Doug Warner Chief Medical Officer | MT |
| 24-07-07 | EFFECTOR Therapeutics, Inc.(OTCPK:EFTR) dropped from S&P TMI Index | CI |
Performance
| 1 week | -8.12% | ||
| 1 month | -34.45% | ||
| 6 months | -88.32% | ||
| Current year | -88.97% | ||
| 1 year | -94.23% |
Volumes
marketsCapital turnover ratio
0
Float rotation
0
Basic data
Market Cap (EUR)
2,822
Market Cap (USD)
2,822
Net sales (USD)
-
Free-Float
99.75 %
Free-Float capitalization (EUR)
3,214
Free-Float capitalization (USD)
2,822
Indicators
Moving average 5 days
1.081
Moving average 100 days
1.66
Price spread / (MMA5)
+0.56%
Price spread / (MMA100)
+54.40%
RSI 9 days
0
RSI 14 days
0
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.47% | -8.12% | -94.23% | - | 2.82K | ||
| -2.19% | +6.01% | +66.90% | +127.13% | 57.65B | ||
| +0.55% | +17.77% | +80.01% | +100.93% | 55.14B | ||
| -0.26% | +3.18% | -13.42% | -13.67% | 23.53B | ||
| +0.06% | +3.19% | +9.36% | +414.51% | 23.11B | ||
| -1.93% | +11.11% | +34.89% | -7.86% | 18.14B | ||
| +0.28% | +5.51% | +36.93% | -30.58% | 16.84B | ||
| -1.08% | +1.25% | +22.72% | +179.82% | 13.68B | ||
| +0.14% | +9.60% | +33.31% | - | 12.97B | ||
| -2.93% | +2.36% | +73.83% | +131.10% | 12.38B | ||
| Average | -0.82% | +5.56% | +25.03% | +112.67% | 23.34B | |
| Weighted average by Cap. | -0.77% | +4.62% | +47.47% | +116.01% |
Historical Quotes: eFFECTOR Therapeutics, Inc.
| Date | Opening | High | Low | Close | Volume | Change |
|---|
Course Extremes
| 1 week | 1.06 | 1.14 | |
| 1 month | 1.06 | 1.62 |
Monthly variations
Annual variations
| 2024 | -88.97% | ||
| 2023 | +2.63% | ||
| 2022 | -94.61% |
- Stock Market
- Stocks
- EFTR Stock
- LWK1 Stock
- Quotes eFFECTOR Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
















